Erlotinib vs Upadacitinib

Erlotinib vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Erlotinib and Upadacitinib.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4; Upadacitinib — C17H19F3N6O.

Molecular Weight: Erlotinib — 393.4380 g/mol; Upadacitinib — 380.3700 g/mol.

Type: Erlotinib — Small molecule; Upadacitinib — Small molecule.